PRTA

Prothena Corp Plc

8.50

Oct 20 • 3:59 PM ET +0.02 (0.24%)

8.50

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology Ireland Small NASD

Peers: ABOS ACIU KRSA ALEC DNLI CGTX AVXL ANVS VYGR ATHE

| Held by: IWM XBI VXF DFAS IBB VTWO IWO FSCC SCHA DFMC

Scroll to Statements

Index	RUT
Market Cap	436.36M
Enterprise Value	155.16M
Income	-43.99M
Sales	54.53M
Book/sh	5.54
Cash/sh	5.61
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	67
IPO	Dec 21, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	8.00
P/B	1.53
P/C	1.51
P/FCF	-
EV/EBITDA	-
EV/Sales	2.85
Quick Ratio	25.05
Current Ratio	25.05
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-0.83
EPS next Y	-1.02
EPS next Q	-0.23
EPS this Y	102.62%
EPS next Y	-962.65%
EPS next 5Y	60.56%
EPS past 3/5Y	-22.46% -10.24%
Sales past 3/5Y	-43.57% 62.56%
EPS Y/Y TTM	85.31%
Sales Y/Y TTM	427.32%
EPS Q/Q	84.75%
Sales Q/Q	-77.15%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	7.69% 139.51%

Insider Own	14.46%
Insider Trans	19.94%
Inst Own	92.65%
Inst Trans	-1.37%
ROA	-12.54%
ROE	-14.39%
ROIC	-15.12%
Gross Margin	93.18%
Oper. Margin	-109.79%
Profit Margin	-80.67%
SMA20	0.43%
SMA50	-3.93%
SMA200	-8.20%
Trades

Shs Outstand	51.74M
Shs Float	43.91M
Short Float	18.24%
Short Ratio	16.47
Short Interest	8.01M
52W High	11.80 -27.97%
52W Low	7.73 9.96%
Volatility	3.41% 5.04%
ATR (14)	0.40
RSI (14)	48.50
Beta	-0.20
Rel Volume	1.09
Avg Volume	486.34K
Volume	529,083

Perf Week	1.67%
Perf Month	-0.12%
Perf Quarter	0.71%
Perf Half Y	-20.34%
Perf YTD	-10.99%
Perf Year	-18.03%
Perf 3Y	-80.59%
Perf 5Y	-85.82%
Perf 10Y	-84.60%
Recom	2.00
Target Price	19.60
Prev Close	8.48
Price	8.50
Change %	0.24%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Downgrade	BofA Securities	Neutral → Underperform	$4
May-27-25	Downgrade	Oppenheimer	Outperform → Perform
May-27-25	Downgrade	Jefferies	Buy → Hold	$6
May-27-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-20-24	Initiated	Chardan Capital Markets	Buy	$40
Jan-30-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $38
Dec-12-23	Initiated	Deutsche Bank	Buy	$62
Apr-24-23	Initiated	SVB Securities	Outperform	$80
Jan-27-23	Initiated	Piper Sandler	Overweight	$94
Nov-04-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$52 → $55
Sep-28-22	Upgrade	BofA Securities	Neutral → Buy
Nov-19-21	Initiated	JMP Securities	Mkt Outperform	$77
Jun-18-21	Upgrade	BofA Securities	Underperform → Neutral	$12 → $49
Jun-08-21	Reiterated	Oppenheimer	Outperform	$45 → $54
May-26-21	Initiated	Citigroup	Buy	$39
Feb-26-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$14 → $28
Feb-12-21	Upgrade	Jefferies	Hold → Buy	$15 → $30
Feb-02-21	Upgrade	BTIG Research	Neutral → Buy	$29
Dec-07-20	Initiated	H.C. Wainwright	Buy	$22
Jul-09-20	Upgrade	Oppenheimer	Perform → Outperform	$16

Show Previous Ratings

Sep-09-26 04:05PM	Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (Business Wire)
Aug-19-26 12:32PM	Real Parkinsons Disease Hope from Jupiter Neurosciences (Exec Edge) +6.66%
Aug-06-26 05:22PM	Prothena: Q2 Earnings Snapshot (Associated Press)
04:05PM	Prothena Reports Second Quarter 2026 Financial Results and Business Highlights (Business Wire)
Jul-30-26 04:05PM	Prothena to Report Second Quarter 2026 Financial Results on August 6 (Business Wire)
04:43PM	Loading…
May-07-26 04:43PM	Prothena: Q1 Earnings Snapshot (Associated Press) -5.90%
04:05PM	Prothena Reports First Quarter 2026 Financial Results and Business Highlights (Business Wire)
Apr-30-26 04:05PM	Prothena to Report First Quarter 2026 Financial Results on May 7 (Business Wire)
Apr-27-26 04:05PM	Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy (Business Wire) +6.67%
Apr-10-26 04:05PM	Prothena Announces Leadership Team Updates (Business Wire)
Mar-21-26 04:05PM	Prothena Partners Present Data Supporting Next Generation Treatments for Parkinsons and Alzheimers Disease at AD/PD 2026 (Business Wire)
Mar-09-26 04:05PM	Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy (Business Wire)
Mar-03-26 09:55AM	Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade (Zacks)
Feb-27-26 04:15PM	Prothena Announces up to $100 Million Share Repurchase Plan (Business Wire) +8.42%
Feb-20-26 11:27AM	Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus (Zacks)
08:30AM	Loading…
08:30AM	Prothena Corporation plc Q4 2025 Earnings Call Summary (Moby)
12:02AM	Prothena Corp PLC (PRTA) Q4 2025 Earnings Call Highlights: Strategic Advancements and Financial ... (GuruFocus.com)
Feb-19-26 07:08PM	Prothena Q4 Earnings Call Highlights (MarketBeat)
05:35PM	Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:34PM	Prothena: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights (Business Wire)
Feb-16-26 09:54AM	Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead? (Zacks)
Feb-13-26 11:40AM	FTRE vs. PRTA: Which Stock Is the Better Value Option? (Zacks)
Feb-12-26 04:05PM	Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 (Business Wire)
Jan-21-26 12:00PM	All You Need to Know About Prothena (PRTA) Rating Upgrade to Buy (Zacks)
Jan-07-26 08:06AM	Fortrea Holdings Inc. (FTRE) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Dec-12-25 04:05PM	Prothena Announces Board of Directors Update (Business Wire)
Nov-19-25 04:05PM	Prothena Announces Poster Presentation on its TDP-43 CYTOPE Program at Neuroscience 2025 (Business Wire)
Nov-11-25 09:00AM	Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA (Business Wire)
Nov-07-25 10:32AM	Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus (Zacks)
05:45PM	Loading…
Nov-06-25 05:45PM	Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:46PM	Prothena: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Third Quarter 2025 Financial Results and Business Highlights (Business Wire)
Oct-30-25 04:05PM	Prothena to Report Third Quarter 2025 Financial Results on November 6 (Business Wire)
Oct-22-25 03:33PM	Prothena Corporation plc (PRTA): A Bull Case Theory (Insider Monkey)
Oct-01-25 04:45PM	Prothenas Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimers Disease (Business Wire)
Sep-11-25 10:01AM	Prothena Down 40% Year to Date: What Lies Ahead for the Stock? (Zacks)
Sep-03-25 11:30AM	Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-25 04:05PM	Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference (Business Wire)
Aug-27-25 04:05PM	Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program (Business Wire)
Aug-08-25 05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive)
Aug-06-25 09:00AM	Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy (Business Wire) +12.66%
Aug-04-25 05:50PM	Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:47PM	Prothena: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Jul-30-25 10:01AM	PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains? (Zacks)
Jul-29-25 10:00AM	Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline (Zacks)
Jul-28-25 04:05PM	Prothena to Report Second Quarter 2025 Financial Results on August 4 (Business Wire)
Jul-24-25 10:46AM	Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well (Zacks)
Jul-17-25 01:07PM	AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies (Zacks)
Jul-04-25 01:51PM	PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects? (Zacks)
Jun-20-25 07:22AM	Prothena to lay off majority of staff; Zealand shares obesity drug data (BioPharma Dive)
Jun-18-25 04:05PM	Prothena Announces Corporate Restructuring (Business Wire)
Jun-17-25 01:30PM	Roche's Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA) (Insider Monkey)
09:16AM	Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus (TipRanks)
Jun-16-25 10:22AM	Roche, waving off study failures, commits to Phase 3 trials for Parkinsons drug (BioPharma Dive) +11.42%
09:49AM	RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development (Zacks)
01:06AM	Prothenas Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease (Business Wire)
May-29-25 03:40PM	Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails (Insider Monkey)
May-28-25 01:55PM	Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform (Insider Monkey)
May-27-25 01:08PM	Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results (Insider Monkey) -30.40%
10:20AM	Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down (Zacks)
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
07:43AM	Why Is Prothena Stock Trading Lower On Tuesday? (Benzinga)
May-26-25 06:16AM	Prothenas Phase III trial for AL amyloidosis treatment misses endpoint (Clinical Trials Arena)
May-23-25 04:05PM	Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint (Business Wire) -30.40%
May-09-25 01:28PM	Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025 (Zacks)
08:29AM	Is Prothena Corporation plc (PRTA) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-08-25 05:50PM	Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:47PM	Prothena: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-07-25 12:44PM	Prothena Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 04:05PM	Prothena to Report First Quarter 2025 Financial Results on May 8 (Business Wire) -5.22%
Apr-16-25 11:49AM	Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi (Zacks)
Feb-21-25 02:15AM	Prothena Corp PLC (PRTA) Q4 2024 Earnings Call Highlights: Strong Financial Position Amidst ... (GuruFocus.com)
Feb-20-25 05:25PM	Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:22PM	Prothena: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights (Business Wire)
Feb-13-25 04:05PM	Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 (Business Wire)
Dec-30-24 04:05PM	Prothena Announces Board of Directors Update (Business Wire) -6.92%
Dec-19-24 04:22PM	Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease (Investor's Business Daily) +33.97%
08:09AM	Prothenas Parkinsons study fails primary endpoint despite some success (Clinical Trials Arena)
01:05AM	Roches Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinsons Disease (Business Wire)
Dec-12-24 11:30AM	Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report? (Zacks)
Nov-12-24 05:55PM	Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:56PM	Prothena: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
Nov-05-24 04:05PM	Prothena to Report Third Quarter 2024 Financial Results on November 12 (Business Wire) +8.71%
Oct-29-24 12:00PM	Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
04:48AM	Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength? (Zacks)
Oct-18-24 03:01PM	State Street Corp's Strategic Reduction in Prothena Corp PLC Holdings (GuruFocus.com)
Sep-27-24 04:05PM	Prothena Announces Leadership Team Updates (Business Wire) -16.56%
Aug-29-24 04:05PM	Prothena to Participate in Upcoming Healthcare Conferences (Business Wire)
Aug-19-24 12:00PM	What Makes Prothena (PRTA) a New Buy Stock (Zacks)
Aug-18-24 12:28AM	Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks (Insider Monkey)
Aug-17-24 08:22AM	7 Best Debt Free Stocks To Buy (Insider Monkey)
Aug-09-24 09:16AM	Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues (Zacks)
Aug-08-24 06:40PM	Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates (Zacks)
05:33PM	Prothena: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Prothena Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SCULLY WILLIAM P	10% Owner	Oct 13 '26	Buy	8.35	100,000	835,480	1,027,000	Oct 15 04:21 PM
SCULLY WILLIAM P	10% Owner	Oct 14 '26	Buy	8.46	10,000	84,569	1,037,000	Oct 15 04:21 PM
SCULLY WILLIAM P	10% Owner	Oct 07 '26	Buy	8.40	125,000	1,050,150	439,000	Oct 09 09:43 AM
SCULLY WILLIAM P	10% Owner	Oct 08 '26	Buy	8.57	90,000	770,904	529,000	Oct 09 09:43 AM
SCULLY WILLIAM P	10% Owner	Oct 02 '26	Buy	8.57	100,000	857,240	314,000	Oct 06 01:53 PM
SCULLY WILLIAM P	10% Owner	Sep 29 '26	Buy	8.68	162,000	1,405,674	214,000	Sep 30 05:10 PM
SCULLY WILLIAM P	10% Owner	Sep 28 '26	Buy	8.60	103,500	889,872	187,000	Sep 29 05:37 PM
SCULLY WILLIAM P	10% Owner	Sep 18 '26	Buy	8.43	100,000	843,460	927,000	Sep 21 04:23 PM
SCULLY WILLIAM P	10% Owner	Sep 02 '26	Buy	9.47	27,000	255,739	827,000	Sep 03 06:23 PM
SCULLY WILLIAM P	10% Owner	Aug 20 '26	Buy	8.79	50,000	439,430	800,000	Aug 21 02:32 PM
SCULLY WILLIAM P	10% Owner	Aug 07 '26	Buy	8.62	34,000	293,053	790,000	Aug 10 03:24 PM
SCULLY WILLIAM P	10% Owner	Aug 07 '26	Buy	8.62	3,500	30,167	83,500	Aug 10 03:24 PM
Kingston Anne Evans	Chief Strategy Officer	Jul 29 '26	Sale	8.47	7,662	64,919	55,782	Jul 30 08:31 PM
Isaacs Michael John	General Counsel & Company Sec.	Jul 29 '26	Sale	8.47	8,386	71,055	35,745	Jul 30 08:30 PM
ANNE KINGSTON	Officer	Jul 29 '26	Proposed Sale	8.47	7,662	64,919		Jul 29 04:12 PM
MICHAEL JOHN ISAACS	Officer	Jul 29 '26	Proposed Sale	8.47	8,386	71,055		Jul 29 04:12 PM
SCULLY WILLIAM P	10% Owner	Jun 16 '26	Buy	7.90	20,000	157,990	756,000	Jun 18 11:38 AM
SCULLY WILLIAM P	10% Owner	Jun 11 '26	Buy	8.17	125,000	1,021,225	1,061,000	Jun 12 05:59 PM
MALECEK MICHAEL J	Previous Officer	Jun 09 '26	Proposed Sale	9.25	80,000	740,000		Jun 09 08:00 AM
SCULLY WILLIAM P	10% Owner	Jun 04 '26	Buy	9.31	50,000	465,295	936,000	Jun 05 01:46 PM
SCULLY WILLIAM P	10% Owner	Jun 02 '26	Buy	9.43	50,000	471,300	886,000	Jun 03 12:41 PM
SCULLY WILLIAM P	10% Owner	May 22 '26	Buy	9.81	100,000	981,300	836,000	May 26 02:51 PM

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

PresidentDr. Gene G. Kinney Ph.D.

Chief Financial OfficerMr. Tran B. Nguyen M.B.A.

Chief Operating OfficerMr. Brandon S. Smith

Chief Scientific OfficerDr. Wagner M. Zago Ph.D.

Chief Accounting Officer & ControllerMs. Karin L. Walker CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRTA

Prothena Corp Plc

Upgrade your Finviz experience